PharmAla Biotech Holdings Inc. announced that it had entered into a binding sales agreement with Numinus Wellness Inc. to provide its GMP LaNeo? MDMA for a prospective clinical trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.19 CAD | +2.70% | 0.00% | +35.71% |
May. 03 | PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy | MT |
Apr. 23 | Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla | CI |
1st Jan change | Capi. | |
---|---|---|
+35.71% | 12.14M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- MDMA Stock
- News Pharmala Biotech Holdings Inc.
- Pharmala Biotech Holdings Inc. Signs Sale Agreement with Numinus